XML 48 R14.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Stock-based Compensation | 12 Months Ended
--- | ---
Dec. 31, 2017
Stock-based Compensation [Abstract] |
Stock-based Compensation | 7. Stock-based Compensation Stock Option Plan OncoCyte has adopted a 2010 Stock Option Plan (the “Plan”) under which 5,200,000 shares of common stock were made available for the grant of stock options or the sale of restricted stock. The Plan also permits OncoCyte to issue such other securities as its Board of Directors or the Compensation Committee administering the Plan may determine. No options may be granted under the Plan more than ten years after the date upon which the Plan was adopted by the Board of Directors, and no options granted under the Plan may be exercised after the expiration of ten years from the date of grant. Under the Plan, options to purchase common stock may be granted to employees, directors and certain consultants at exercise prices not less than the fair market value of common stock at date of grant, subject to certain limited exceptions for options granted in substitution of other options. Options may be fully exercisable immediately, or may be exercisable according to a schedule or conditions specified by the Board of Directors or the Compensation Committee. Generally, OncoCyte stock options have service related vesting conditions based on the continued performance of services for OncoCyte. The Plan also permits OncoCyte to award restricted stock for services rendered or to sell common stock to employees subject to vesting provisions under restricted stock agreements that provide for forfeiture of unvested shares upon the occurrence of specified events. OncoCyte may permit employees or consultants, but not officers or directors, who purchase stock under restricted stock purchase agreements, to pay for their shares by delivering a promissory note that is secured by a pledge of their shares. To date, only stock options have been issued under the Plan. As discussed in Note 4, OncoCyte may grant stock options to employees of BioTime, or employees of other BioTime subsidiaries, who perform services for OncoCyte. OncoCyte records stock-based compensation expense in the accompanying statements of operations for those services performed in the periods presented. Stock Options Options granted under the Plan may be either “incentive stock options” within the meaning of Section 422(b) of the Internal Revenue Code of 1986, as amended (the “Code”), or non-qualified stock options. Incentive stock options may be granted only to OncoCyte employees and employees of its subsidiaries, if any. The exercise price of stock options granted under the Plan must be equal to the fair market value of OncoCyte common stock on the date the option is granted. In the case of an optionee who, at the time of grant, owns more than 10% of the combined voting power of all classes of OncoCyte stock, the exercise price of any incentive stock option must be at least 110% of the fair market value of the common stock on the grant date, and the term of the option may be no longer than five years. The aggregate fair market value of OncoCyte common stock (determined as of the grant date of the option) with respect to which incentive stock options become exercisable for the first time by an optionee in any calendar year may not exceed $100,000. The options’ exercise price may be payable in cash or in common stock having a fair market value equal to the exercise price, or in a combination of cash and common stock, or other legal consideration for the issuance of stock as the Board of Directors or Compensation Committee may approve. Incentive stock options granted under the Plan are nontransferable except by will or the laws of descent and distribution and may be exercised only during employment or within three months after termination of such employment, subject to certain exceptions in the event of the death or disability of the optionee. Options other than incentive stock options under the Code are also nontransferable except by will or the laws of descent and distribution, except to the extent that the Board of Directors or Committee permits the optionee to transfer an option to a family member, a trust for family members, or other persons approved by the Board of Directors or Committee in its discretion. Generally, options will be exercisable only while the optionee remains an employee, director or consultant, or during a specific period thereafter as approved by the Board of Directors or Committee, but in the case of the termination of an employee, director, or consultant’s services due to death or disability, the period for exercising a vested option shall be extended to the earlier of 12 months after termination or the expiration date of the option. The number of shares of common stock covered by the Plan, and the number of shares of common stock and the exercise price per share of each outstanding option, shall be proportionately adjusted for any increase or decrease in the number of issued and outstanding shares of common stock resulting from a subdivision or consolidation of shares or the payment of a stock dividend, or any other increase or decrease in the number of issued and outstanding shares of common stock effected without receipt of consideration by OncoCyte. Options Granted As of December 31, 2017, 1,384,198 shares were available for future grants under the Plan. A summary of OncoCyte stock option activity under the Plan and related information follows (in thousands except weighted average exercise price):
Options |  | Shares Available for Grant |  |  | Number of Options Outstanding |  |  | Weighted Average Exercise Price |
Total at January 1, 2016 |  |  | 1,757 |  |  |  | 2,240 |  |  | $ | 2.03 |
Options granted |  |  | (962 | ) |  |  | 962 |  |  |  | 3.58 |
Options exercised |  |  | - |  |  |  | (100 | ) |  |  | 2.19 |
Options forfeited, cancelled or expired |  |  | 85 |  |  |  | (85 | ) |  |  | 2.00 |
Total at December 31, 2016 |  |  | 880 |  |  |  | 3,017 |  |  |  | 2.52 |
Increase in pool |  |  | 1,200 |  |  |  | - |  |  |  |  |
Options granted |  |  | (896 | ) |  |  | 896 |  |  |  | 5.17 |
Options exercised |  |  | - |  |  |  | (323 | ) |  |  | 1.89 |
Options forfeited, cancelled or expired |  |  | 200 |  |  |  | (200 | ) |  |  | 3.11 |
Total at December 31, 2017 |  |  | 1,384 |  |  |  | 3,390 |  |  | $ | 3.25 |
Exercisable at December 31, 2017 |  |  |  |  |  |  | 1,835 |  |  | $ | 2.48 |
At December 31, 2017 and 2016, OncoCyte had approximately $1.6 million and $2.7 million, respectively, of total unrecognized compensation expense related to the Plan that will be recognized over a weighted-average period of approximately 2.5 and 2.4 years, respectively. OncoCyte recorded stock-based compensation expense in the following categories on the accompanying statements of operations for the years ended December 31, 2017, 2016 and 2015 (in thousands):
|  | Year Ended December 31, |
|  | 2017 |  |  | 2016 |  |  | 2015 |
Research and development |  | $ | 668 |  |  | $ | 312 |  |  | $ | 456 |
General and administrative |  |  | 841 |  |  |  | 610 |  |  |  | 1,359 |
Sales and marketing |  |  | 121 |  |  |  | - |  |  |  | - |
Total stock-based compensation expense |  | $ | 1,630 |  |  | $ | 922 |  |  | $ | 1,815 |
The assumptions that were used to calculate the grant date fair value of OncoCyte’s employee and non-employee stock option grants for the years ended December 31, 2017, 2016 and 2015 were as follows.
|  | Year Ended December 31, |
|  | 2017 |  |  | 2016 |  |  | 2015 |
Expected life (in years) |  |  | 6.15 |  |  |  |  | 6.21 |  |  |  |  | 6.83 |  |
Risk-free interest rates |  |  | 2.03 | % |  |  |  | 1.46 | % |  |  |  | 1.87 | % |
Volatility |  |  | 66.01 | % |  |  |  | 64.64 | % |  |  |  | 74.15 | % |
Dividend yield |  |  | - | % |  |  |  | - | % |  |  |  | - | % |
With the adoption of ASU 2016-09, effectively January 1, 2017, forfeitures are accounted for as they occur instead of based on the number of awards that were expected to vest. The determination of stock-based compensation is inherently uncertain and subjective and involves the application of valuation models and assumptions requiring the use of judgment. If OncoCyte had made different assumptions, its stock-based compensation expense, and net loss for years ended December 31, 2017, 2016 and 2015, may have been significantly different.

X
- Definition The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 50 -URI http://asc.fasb.org/subtopic&trid=2208855 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration